Protalix BioTherapeutics(PLX)

POST2.250.01+0.39%18:50 EDT

2.24+0.07+3.23%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
  PR Newswire · 03-10
  Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
- Balanced Outlook for PLUXEE N.V. Amid Spin-Out Opportunities and Market Challenges
  TIPRANKS · 02-10
  Balanced Outlook for PLUXEE N.V. Amid Spin-Out Opportunities and Market Challenges
- 3 US Penny Stocks With Market Caps Under $400M To Watch
  Simply Wall St. · 02-06
  3 US Penny Stocks With Market Caps Under $400M To Watch
- Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
  PR Newswire · 02-04
  Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
- Protalix price target raised to $15 from $10 at H.C. Wainwright
  TIPRANKS · 02-03
  Protalix price target raised to $15 from $10 at H.C. Wainwright
- PLX: Revisiting the Thesis
  Zacks Small Cap Research · 02-03
  PLX: Revisiting the Thesis
- Barclays Sticks to Their Hold Rating for PLUXEE N.V. (PLX)
  TIPRANKS · 01-30
  Barclays Sticks to Their Hold Rating for PLUXEE N.V. (PLX)
- Kepler Capital Sticks to Its Buy Rating for PLUXEE N.V. (PLX)
  TIPRANKS · 01-10
  Kepler Capital Sticks to Its Buy Rating for PLUXEE N.V. (PLX)
- PLUXEE N.V. (PLX) Gets a Hold from UBS
  TIPRANKS · 01-09
  PLUXEE N.V. (PLX) Gets a Hold from UBS
- Protalix BioTherapeutics Issues 2025 Letter to Stockholders
  PR Newswire · 2024-12-23
  Protalix BioTherapeutics Issues 2025 Letter to Stockholders
- Barclays Sticks to Their Hold Rating for PLUXEE N.V. (PLX)
  TIPRANKS · 2024-12-13
  Barclays Sticks to Their Hold Rating for PLUXEE N.V. (PLX)
- Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
  PR Newswire · 2024-12-09
  Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
- Pluri assesses readiness to mass produce PLX-R18
  TIPRANKS · 2024-11-25
  Pluri assesses readiness to mass produce PLX-R18
- PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
  Zacks Small Cap Research · 2024-11-15
  PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
- Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
  GuruFocus.com · 2024-11-15
  Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
- Protalix BioTherapeutics Reports Strong Q3 2024 Results
  TIPRANKS · 2024-11-15
  Protalix BioTherapeutics Reports Strong Q3 2024 Results
- Protalix: Q3 Earnings Snapshot
  Associated Press Finance · 2024-11-14
  Protalix: Q3 Earnings Snapshot
- Protalix BioTherapeutics Q3 2024 GAAP EPS $0.03 Misses $0.06 Estimate, Sales $17.96M Beat $16.26M Estimate
  Benzinga · 2024-11-14
  Protalix BioTherapeutics Q3 2024 GAAP EPS $0.03 Misses $0.06 Estimate, Sales $17.96M Beat $16.26M Estimate
- Press Release: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
  Dow Jones · 2024-11-14
  Press Release: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
- Kepler Capital Remains a Buy on PLUXEE N.V. (PLX)
  TIPRANKS · 2024-11-10
  Kepler Capital Remains a Buy on PLUXEE N.V. (PLX)
Company Profile
Company Name
Protalix BioTherapeutics
Market
AMEX
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.protalix.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
- 2024-12-31
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-12-23
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-11-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-10-25
  Beneficial Ownership Change
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 2024-10-25
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-08-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-08-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-07-01
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2024-06-28
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-05-10
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-05-10
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-03-14
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 2024-03-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-01-02
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

1D
5D
Day
Week
Month

Loading ...

High

2.24

Open

2.21

Volume%

0.79

Low

2.16

2.17

T/O Rate

1.27%

抱歉，当前请求异常(-1)

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

Protalix BioTherapeutics(PLX)

Company Profile